Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports
British Journal of Clinical Pharmacology2020Vol. 87(3), pp. 1432–1442
Citations Over TimeTop 10% of 2020 papers
Abstract
In a real-world setting, HCQ/CQ treatment is associated with higher reporting rates of various CVAEs, particularly cardiomyopathy, QT prolongation, cardiac arrhythmias and heart failure. HCQ/CQ-associated CVAEs result in high rates of severe outcomes and should be carefully considered as an off-label indication, especially for patients with cardiac disorders.
Related Papers
- → Chloroquine and hydroxychloroyuine therapy in rheumatoid arthritis(1962)45 cited
- → Chloroquine and Hydroxychloroquine could be an Available Weapons to Treat COVID-19 Associated Pneumonia(2020)3 cited
- → Chloroquine/Hydroxychloroquine in the Treatment and Prophylaxis of COVID-19 Disease(2020)
- → Do Chloroquine and Hydroxychloroquine Treat COVID-19?(2021)
- → Do Chloroquine and Hydroxychloroquine Treat COVID-19?(2021)